Business Wire

Armis Launches Armis Centrix™, the AI-powered Cyber Exposure Management Platform

13.9.2023 15:00:00 EEST | Business Wire | Press release

Share

Armis, the asset intelligence cybersecurity company, today announced the launch of Armis Centrix™, the AI-powered cyber exposure management platform. Armis Centrix™ is a seamless, frictionless, cloud-based platform that proactively secures all your assets, remediates vulnerabilities, blocks threats and protects your entire attack surface.

Armis Centrix™ enables organizations to discover, contextualize, enrich and profile every asset in their environment whilst also building a line of defense by leveraging Armis Centrix™ Asset Intelligence risk scores, policies, alerting and visualizations and most importantly: prioritize efforts against the exposures that matter to your business. Armis Centrix™ also integrates with existing enforcement and ticketing tools to establish end-to-end workflows and true risk lifecycle management and track risk reduction efforts to easily report on progress made. Armis Centrix™ takes proactive measures, detects threats & stops attacks to establish operational workflows and track risk reduction.

“In a perimeter-less world, where assets are digitally connected, traditional cybersecurity boundaries no longer exist. Legacy on-premise systems and point solutions are no longer fit for purpose leaving your attack surface and most critical assets open and exposed to cyber criminals and multiple bad actors,” said Nadir Izrael, CTO and Co-Founder, Armis. “The sheer scale and dynamic nature of the attack surface necessitates an entirely different, AI-driven approach, and that’s what Armis Centrix™ is - the AI that powers a suite of powerful tools for managing cyber risk exposure.”

Armis Centrix™ helps organizations see, protect and manage their entire attack surface, continuously safeguarding their mission-critical assets from cyber threats. Born in the cloud and fueled by AI, only Armis Centrix™ delivers a true modular approach to cyber exposure management covering the most critical cybersecurity needs for our clients across 4 solutions:

  • Asset management and security - Complete asset inventory of all asset types allowing any organization to see and secure the attack surface
  • OT/IOT security - See and secure OT/IOT networks and physical assets, ensure uptime and build an effective & comprehensive security strategy
  • Medical device security - Complete visibility and security for all medical devices, clinical assets and the entire healthcare ecosystem - with zero disruption to patient care
  • Vulnerability prioritization and remediation - Consolidate, prioritize and remediate all vulnerabilities; improve mean time to remediation (MTTR) with automatic remediation and ticketing workflows

“This is a revolutionary advancement that will change the way in which companies answer key questions regarding their cybersecurity posture,” said Dana Gilboa, Chief Product Officer, Armis. “Armis can help organizations mitigate their cyber asset risks and protect the entire attack surface by providing the needed intelligence to align security and business efforts. With this approach, we can ultimately provide organizations with the peace of mind they need, allowing them to see, protect and manage all their critical assets.”

Armis Centrix™ is industry-agnostic, allowing Manufacturing, Health and Medical, Information Technology, Energy and Utilities, Financial Services, Transportation, Telecommunications and Media, Public Sector and many more to benefit from its capabilities. Additionally, Armis collaborates with the world’s premier global technology vendors to ensure its customers can seamlessly integrate the Armis Centrix™ platform with existing IT and security stacks.

If you would like to know more about Armis Centrix™, the cyber exposure management platform, visit armis.com/centrix or contact us at info@armis.com.

About Armis

Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, secure, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society safe and secure 24/7. Armis is a privately held company headquartered in California.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye